HCV drug combo linked to side effects after liver transplant

05/16/2013 | Aidsmap

Treating hepatitis C-positive patients who underwent a liver transplant with a combination of three drugs -- pegylated interferon, ribavirin and telaprevir -- increased sustained viral response rates even for difficult cases, but adverse events were also common, according to findings presented at a liver meeting. Among the adverse events were the need for transfusions to address blood cell deficiencies. The study evaluated data from six U.S. centers.

View Full Article in:

Aidsmap

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA